The Influence of RDC on Tumor Cells

The radionuclide and the targeting molecule are two key parts of RDC, as the radionuclide plays an effective role in RDC and the targeting molecule works as the delivery vehicle. Radionuclides are capable to damage cancer cells by decaying and emitting alpha- or beta- radioactive rays. The affinity of delivery molecules for targeted molecules expressed in cancer cells is a crucial step in the efficacy of RDC drugs. Another key point is the selection of the right radionuclide to damage the DNA and inhibit other metabolic processes of tumor cells.

Tumor Cell as An in Vitro Model

In the preclinical phase of drug development, in vitro and in vivo toxicology and efficacy testing studies are essential to determine the threshold and usefulness of how the RDC works on diseased tissue. In the context of RDC development, the tumor inhibition potency analysis can provide useful information on the pathophysiological processes, which is directly correlated to the damage of cancer cells by radionuclide and can describe tumor growth and tumor inhibition due to the RDC.

For example, the in vitro effects of various treatments, including BLS (Blank Liposomes), GAQ (Aqueous Glutathione Disulfide), GLS (Glutathione Disulfide Liposomes) on apoptosis of NCI-H226 cancer cell is evaluated by TUNEL assay.